Australia
Extended Abstract
Clinical Cardiology Congress 2020: An Audit of Glucose Lowering Therapies In Patients With Type 2 Diabetes And Hospitalisation for Heart Failure - Meor Azraai - The Royal Melbourne Hospital & NorthWestern Mental Health.
Author(s): Meor Azraai
Background: The CSANZ Heart Failure (HF) guidelines state that sodium-glucose co-transporter-2 inhibitors (SGLT2i) are the preferred second line agent in patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease to reduce CV events and HF hospitalisation.
Aim: To review glucose lowering therapies in patients with T2DM who had been hospitalised with HF at Austin Health, and the percentage of patients .. Read More»
